Trump Imposes 100% Tariffs on Drugs

What's happened

On April 2, 2026, President Trump signed executive orders imposing up to 100% tariffs on foreign-made patented pharmaceuticals that do not meet pricing or US manufacturing conditions. Companies with pricing deals and US production face zero tariffs; others face escalating tariffs over four years. The orders also revise tariffs on steel, aluminum, and copper products to be based on full US market value.

What's behind the headline?

Strategic Use of Tariffs to Reshape Pharma and Metals Industries

President Trump's new tariffs represent a calculated escalation in his trade policy, leveraging import duties to force pharmaceutical companies to lower prices and increase US manufacturing. The zero-percent tariff exemption for companies that sign 'most favored nation' pricing deals and build US facilities creates a clear incentive structure favoring large, established firms like Pfizer and Eli Lilly, who have already signed such deals.

Impact on Smaller Drugmakers and Market Dynamics

Smaller and mid-sized drugmakers face a steep tariff climb—from 20% to 100% over four years—unless they negotiate deals or onshore production. This creates a two-tiered system that could disadvantage emerging companies lacking diversified portfolios, potentially reducing competition and innovation in the US pharmaceutical market.

National Security Framing and Political Timing

Framing tariffs as necessary to protect national security underscores the administration's broader narrative linking economic policy to geopolitical strength. The timing on the first anniversary of 'Liberation Day' tariffs signals a recommitment to aggressive trade measures despite recent legal setbacks.

Metals Tariff Recalculation and Industry Effects

Adjusting tariffs on steel, aluminum, and copper to be based on full US market value rather than foreign production costs closes loopholes that importers exploited. This will raise costs for products with significant metal content, affecting industries reliant on imported components and finished goods.

Forecast and Consequences

The tariffs will likely accelerate pharmaceutical onshoring but raise drug costs in the short term due to increased production expenses and tariffs on imports. The metals tariff changes will protect domestic producers but increase costs for manufacturers using imported metal components. Politically, these moves reinforce Trump's trade agenda but risk backlash from smaller drugmakers and industries dependent on imported metals.

How we got here

Since the start of his second term, Trump has pursued aggressive import tariffs to protect US industries and lower drug prices. Last year’s 'Liberation Day' tariffs were overturned by the Supreme Court in February 2026. The new orders target pharmaceutical imports and metals, aiming to boost domestic production and address national security concerns.

Our analysis

The New York Times' Ana Swanson highlights the administration's dual focus on pharmaceuticals and metals, noting the simplification of tariffs on products with significant metal content: "Any product where steel, aluminum or copper makes up more than 15 percent by weight will pay a flat 25 percent tariff on the entire value of the product." The Guardian's Lauren Aratani emphasizes the creation of a "two-tiered system of exemptions," warning that mid-sized drugmakers "lack diversified portfolios to absorb these sudden cost increases." She also notes the exemption of generic drugs and specialty medicines, which make up the majority of US prescriptions. Al Jazeera and France 24 provide detailed accounts of the tariff structure, with Al Jazeera quoting a senior administration official who said companies have months to negotiate before 100% tariffs apply, and noting 17 pricing deals with major drugmakers, 13 signed. The NY Post's Steven Nelson underscores the tariff relief for large companies that have pledged 'most favored nations' pricing and US production, while smaller firms face escalating tariffs. Politico frames the tariffs as part of a broader trade strategy, marking the anniversary of the original 'Liberation Day' tariffs and highlighting the administration's efforts to cap tariffs for countries with trade agreements. The coverage collectively illustrates a complex policy balancing protectionism, negotiation leverage, and industry incentives.

Go deeper

How will these tariffs affect drug prices for consumers?
What incentives do pharmaceutical companies have to build US manufacturing facilities?
How will the new metals tariff calculations impact US manufacturers?